Personalized dosimetry of 131I-rituximab radioimmunotherapy of lymphoma

被引：0
|
作者：
Boucek, J. A. [1 ]
Turner, J. [1 ]
机构：
[1] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [31] High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab
    Becker, W
    Behr, T
    ANNALS OF HEMATOLOGY, 2001, 80 : B130 - B131
  • [32] High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab
    W. Becker
    Th. Behr
    Annals of Hematology, 2001, 80 (Suppl 3) : B130 - B131
  • [33] Repeated radioimmunotherapy (RIT) with 131I-rituximab for patients with low grade and aggressive relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye Jin
    Lee, Seung-Sook
    Kim, Kyeong Min
    Lim, Sang Moo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [34] Cellular Internalization and Mechanism of Cytotoxicity of 131I-Rituximab in Raji Cells
    Kumar, Chandan
    Pandey, B. N.
    Samuel, Grace
    Venkatesh, Meera
    JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2013, 32 (02) : 91 - 99
  • [35] The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy
    Choi, Joon Ho
    Lim, Ilhan
    Byun, Byung Hyun
    Kim, Byung Il
    Choi, Chang Woon
    Kang, Hye Jin
    Shin, Dong-Yeop
    Lim, Sang Moo
    PLOS ONE, 2022, 17 (09):
  • [36] Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 117 (01) : 45 - 52
  • [37] Low dose of 131I-F(ab′)2-Rituximab and 131I-Rituximab induces G1 arrest and apoptosis in Raji cells (Burkitt's lymphoma)
    Suman, Shishu Kant
    Kameswaran, Mythili
    Dash, Ashutosh
    INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 2020, 58 (10) : 680 - 690
  • [38] Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography
    McQuillan, Andrew D.
    Macdonald, William B. G.
    Turner, J. Harvey
    LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1271 - 1277
  • [39] The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab
    Wahl, RL
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 31 - 38
  • [40] Improved Quantification of 18F-FDG PET during 131I-Rituximab Therapy on Mouse Lymphoma Models after 131I Prompt Emission Correction
    Lee, Young Sub
    Kim, Hee-Joung
    Kim, Jin Su
    DIAGNOSTICS, 2019, 9 (04)
12345